BioSpace News Archive

TScan Therapeutics, Inc. announced that the Company will participate in a fireside chat at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on Thursday, June 8, 2023 at 8:00 a.m. Eastern Time.

Jnana Therapeutics announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m. ET.

BioXcel Therapeutics, Inc. announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in fireside chats at two upcoming investor conferences.

IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 1:30 p.m. EDT in New York.

Tango Therapeutics, Inc. announced that members of the management team are scheduled to participate in the following upcoming investor conferences in June.

Avalo Therapeutics, Inc. announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 11:00 a.m. ET at the Marriott Marquis in New York, NY.

Plus Therapeutics, Inc. announced that Marc Hedrick, M.D., President and Chief Executive Officer, will provide a comprehensive update of the Company’s recent activity and progress to date during a presentation at the 2023 Virtual June Investor Summit on Thursday, June 1, 2023, at 2:00 p.m. ET.

Axsome Therapeutics, Inc. announced presentations on Sunosi® at SLEEP 2023, the annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held in Indianapolis, Ind., from June 3-7, 2023.

Milestone Pharmaceuticals Inc. today announced that members of its management team will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:30 a.m. ET.

Abilita Bio, a leader in enabling the discovery of membrane protein-targeted therapeutics, announced today the company changed its name to Abilita Therapeutics.